Aaron Cranston

3.7k total citations · 1 hit paper
42 papers, 2.8k citations indexed

About

Aaron Cranston is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Aaron Cranston has authored 42 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 24 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Aaron Cranston's work include DNA Repair Mechanisms (10 papers), PARP inhibition in cancer therapy (10 papers) and Genetic factors in colorectal cancer (9 papers). Aaron Cranston is often cited by papers focused on DNA Repair Mechanisms (10 papers), PARP inhibition in cancer therapy (10 papers) and Genetic factors in colorectal cancer (9 papers). Aaron Cranston collaborates with scholars based in United Kingdom, United States and Netherlands. Aaron Cranston's co-authors include Mark J. O’Connor, Alan Lau, Niall M.B. Martin, Richard Fishel, Janneke E. Jaspers, Jos Jonkers, Sven Rottenberg, Ariena Kersbergen, Serge A.L. Zander and Piet Borst and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Genetics and The Journal of Experimental Medicine.

In The Last Decade

Aaron Cranston

38 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

2008 762 citations Sven Rottenberg, Janneke E. Jaspers et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aaron Cranston United Kingdom	18	1.9k	1.8k	467	343	329	42	2.8k
Janneke E. Jaspers Netherlands	15	1.4k 0.7×	1.5k 0.9×	388 0.8×	208 0.6×	68 0.2×	17	2.0k
Antonella Papa United States	18	2.4k 1.3×	855 0.5×	223 0.5×	247 0.7×	296 0.9×	29	3.1k
Claudia Kowolik United States	26	1.6k 0.8×	1.3k 0.7×	297 0.6×	739 2.2×	288 0.9×	43	2.9k
Eline van der Burg Netherlands	13	1.2k 0.6×	1.3k 0.7×	342 0.7×	134 0.4×	75 0.2×	19	1.7k
Damian A. Johnson United Kingdom	4	3.5k 1.9×	3.6k 2.0×	874 1.9×	392 1.1×	227 0.7×	4	4.9k
Heng‐Huan Lee United States	23	1.8k 1.0×	1.9k 1.1×	112 0.2×	831 2.4×	159 0.5×	56	3.4k
Charlotte Knights United Kingdom	6	3.8k 2.0×	3.9k 2.2×	914 2.0×	436 1.3×	239 0.7×	13	5.4k
T. Khanh United States	26	1.6k 0.9×	991 0.6×	142 0.3×	238 0.7×	180 0.5×	57	2.5k
Daniel Nava Rodrigues United Kingdom	26	948 0.5×	878 0.5×	208 0.4×	160 0.5×	148 0.4×	54	2.2k
Rachel Brough United Kingdom	21	2.4k 1.3×	2.1k 1.2×	480 1.0×	177 0.5×	243 0.7×	39	3.1k

Countries citing papers authored by Aaron Cranston

Since Specialization

Citations

This map shows the geographic impact of Aaron Cranston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Cranston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Cranston more than expected).

Fields of papers citing papers by Aaron Cranston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Cranston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Cranston. The network helps show where Aaron Cranston may publish in the future.

Co-authorship network of co-authors of Aaron Cranston

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Cranston. A scholar is included among the top collaborators of Aaron Cranston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Cranston. Aaron Cranston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wappett, Mark, Julien Daubriac, Ian Lobb, et al.. (2024). USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF. Clinical and Translational Medicine. 14(4). e1648–e1648. 9 indexed citations

Helali, Aya El, Ruth Plummer, Gordon C. Jayson, et al.. (2022). A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. British Journal of Cancer. 127(1). 92–101. 9 indexed citations

Nesbit, M. Andrew, et al.. (2022). Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders. SHILAP Revista de lepidopterología. 2(2). 100150–100150. 2 indexed citations

Cranston, Aaron, et al.. (2019). A Three-Dimensional In Vitro Coculture Model to Quantify Breast Epithelial Cell Adhesion to Endothelial Cells. Tissue Engineering Part C Methods. 25(10). 609–618. 10 indexed citations

Helali, Aya El, Ruth Plummer, Gordon C. Jayson, et al.. (2017). A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours. Annals of Oncology. 28. v128–v128. 5 indexed citations

O’Connor, Lenka Oplustil, Stuart L. Rulten, Aaron Cranston, et al.. (2016). The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer Research. 76(20). 6084–6094. 60 indexed citations

Cranston, Aaron, et al.. (2016). Activity Based Profiling of Deubiquitylating Enzymes and Inhibitors in Animal Tissues. Methods in molecular biology. 1449. 411–419. 2 indexed citations

Jaspers, Janneke E., Ariena Kersbergen, Ute Boon, et al.. (2012). Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors. Cancer Discovery. 3(1). 68–81. 388 indexed citations

McAlpine, Jessica N., Hui Xue, Jun Guan, et al.. (2010). Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. Clinical Cancer Research. 17(4). 783–791. 52 indexed citations

10.

Hay, Trevor, James R. Matthews, Alan Lau, et al.. (2009). Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin. Cancer Research. 69(9). 3850–3855. 94 indexed citations

11.

Knights, Charlotte, Lucy C. Riches, Alan Lau, et al.. (2009). Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer. Cancer Research. 69. 5494–5494. 1 indexed citations

12.

Knights, Charlotte, Christine M. Chresta, Lucy C. Riches, et al.. (2009). Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer. Molecular Cancer Therapeutics. 8(12_Supplement). A114–A114. 5 indexed citations

13.

Carniti, Cristiana, Sara Belluco, Elena Riccardi, et al.. (2006). The RetC620R Mutation Affects Renal and Enteric Development in a Mouse Model of Hirschsprung's Disease. American Journal Of Pathology. 168(4). 1262–1275. 28 indexed citations

14.

Drosten, Matthias, Gero Hilken, Michelle Bockmann, et al.. (2004). Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma. JNCI Journal of the National Cancer Institute. 96(16). 1231–1239. 57 indexed citations

15.

Cranston, Aaron, Louise Howard, & C. V. Howard. (2004). Quantitative Phenotyping as an Efficient Means to Estimate C-Cell Number in a Knock-in Mouse Model of MEN2B. Transgenic Research. 13(4). 339–348. 3 indexed citations

16.

Reynolds, Lucinda F., Ken Jones, Douglas J. Winton, et al.. (2001). C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Oncogene. 20(30). 3986–3994. 39 indexed citations

17.

Fishel, Richard, Sonia N. Acharya, Mark Berardini, et al.. (2000). Signaling Mismatch Repair: The Mechanics of an Adenosine-Nucleotide Molecular Switch. Cold Spring Harbor Symposia on Quantitative Biology. 65(0). 217–224. 13 indexed citations

18.

Sevignani, Cinzia, Aaron Cranston, Renato V. Iozzo, Richard Fishel, & Bruno Calabretta. (1999). Spontaneous and mutagen-induced transformation of primary cultures of Msh2-/- p53-/- colonocytes.. PubMed. 59(23). 5882–6. 7 indexed citations

19.

Cranston, Aaron & Richard Fishel. (1999). Female embryonic lethality in Msh2Trp53 nullizygous mice is strain dependent. Mammalian Genome. 10(10). 1020–1022. 14 indexed citations

20.

Phung, Quy H., David B. Winter, Aaron Cranston, et al.. (1998). Increased Hypermutation at G and C Nucleotides in Immunoglobulin Variable Genes from Mice Deficient in the MSH2 Mismatch Repair Protein. The Journal of Experimental Medicine. 187(11). 1745–1751. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact